Profil
Pamela Strode worked as a Senior VP of Regulatory Affairs and Quality Assurance at Fulcrum Therapeutics, Inc. She also held the position of Vice President of Regulatory Affairs at Cerulean Pharma, Inc. and VP of Regulatory Affairs & Quality Assurance at Epizyme, Inc. She completed her undergraduate degree at Rutgers State University of New Jersey and her graduate degree at Temple University in Pennsylvania.
Anciens postes connus de Pamela Strode
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | Conseiller Juridique Général | 01/08/2019 |
| FULCRUM THERAPEUTICS, INC. | Conseiller Juridique Général | - |
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Conseiller Juridique Général | - |
Formation de Pamela Strode
| Rutgers State University of New Jersey | Undergraduate Degree |
| Temple University (Pennsylvania) | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |